STING-mediated cancer immunotherapy: emerging modalities and beyond

Ramesha Hanumanthappa

doi:10.1016/j.tips.2026.07.002

STING-mediated cancer immunotherapy: emerging modalities and beyond

2026-07-25

0

PRE

AI

R

Ramesha Hanumanthappa

N

Nandakumar Dalavaikodihalli Nanjaiah

S

Sudhir H. Ranganath *

DOI：10.1016/j.tips.2026.07.002

Original

Original request for help

Save

Abstract

En 中文

The clinical translation of stimulator of interferon genes (STING)agonist-based cancer immunotherapy is limited by uncontrolled and sustained STING activation, which leads to immune exhaustion and systemic toxicity. In this forum, we critically analyze recent advances, including stimuli-responsive, biomimetic, pulsatile, intracellular-triggered release, and synergistic systems that enable precise spatiotemporal STING activation, as well as associated gaps in clinical translation. Finally, we present futuristic perspectives on next-generation STING-based cancer immunotherapy strategies.

STING-mediated cancer immunotherapy: emerging modalities and beyond

Abstract

Journal

Organization